Does Iron Chelators Interact with Marnetegragene Autotemcel?
CDI records a major classification for Iron Chelators and Marnetegragene Autotemcel. The stored summary is: Discontinue at least 7 days prior to myeloablative conditioning initiation. Avoid myelosuppressive iron chelators for 6 months after ZYNTEGLO infusion. Consider non-myelosuppressive alternatives or phlebotomy. The mechanism involves drug-drug interactions with myeloablative conditioning agents; some iron chelators are myelosuppressive. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Drug-drug interactions with myeloablative conditioning agents; some iron chelators are myelosuppressive
What To Tell Your Doctor or Pharmacist
If you are taking Iron Chelators and your doctor is considering prescribing Marnetegragene Autotemcel (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider